Filing Flows › Lipocine (LPCN) › R&D spending
Lipocine (LPCN) R&D spending by quarter
Lipocine's R&D spending was $2.1M in Q3 2026 (third quarter 2026), +1% from Q2 2026. Over the last 7 quarters it ranged from $1.1M (Q1 2025) to $2.8M (Q1 2026).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $2.1M | +1% | -24% |
| Q2 2026 | $2.0M | -26% | -4% |
| Q1 2026 | $2.8M | +3% | +160% |
| Q4 2025 | $2.7M | -1% | — |
| Q3 2025 | $2.7M | +27% | — |
| Q2 2025 | $2.1M | +101% | — |
| Q1 2025 | $1.1M | — | — |
Q3 2026 at a glance
Lipocine, Q3 2026: revenue $2.3M (20× year over year), operating margin -37.9%, net loss $666K, operating cash flow −$1.8M. The chart follows the revenue to costs, profit and cash.
Questions
What is Lipocine's R&D spending?
Lipocine's R&D spending was $2.1M in Q3 2026 (third quarter 2026), +1% from Q2 2026.
How has Lipocine's R&D spending changed?
Over the last 7 quarters it ranged from $1.1M (Q1 2025) to $2.8M (Q1 2026).